Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182761 | 0.80 | MAPK1 (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL13740726 | 0.78 | MAPK1 (0.45) | MAPK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13740576 | 0.73 | MAPK1 (0.45) | MAPK1MEN1KMT2A | |
| SCHEMBL615681 | 0.72 | KDM4E (0.35) | KDM4EALDH1A1ALOX15JAK1POLB | |
| SCHEMBL8377244 | 0.72 | HSD11B1 (0.37) | KDM4EALDH1A1ALOX15JAK1POLB | |
| SCHEMBL5071115 | 0.71 | MAPK1 (0.46) | MAPK1MEN1KMT2A | |
| SCHEMBL5415021 | 0.68 | MAPK1 (0.48) | MAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL22959616 | 0.68 | KDM4E (0.33) | KDM4EALDH1A1ALOX15JAK1 | |
| SCHEMBL7848036 | 0.68 | KDM4E (0.33) | KDM4EALDH1A1ALOX15JAK1 | |
| SCHEMBL6018054 | 0.67 | MAPK1 (0.81) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-2233479-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | Liverpool School of Tropical Medicine (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | NR1H2, NR1H3, NR1I2 | MAPK1 4146/4885MEN1 2637/4885KMT2A 1168/4885 |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | NR1H3, NR1H2, NR1I2 | MAPK1 3947/4885MEN1 2871/4885KMT2A 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.